染色质凝聚调节因子2的人类泛癌系统分析
A human pan-cancer system analysis of regulator of chromatin condensation 2.
作者信息
Gong Siming, Wu Hao, Wu Changwu, Duan Yingjuan, Zhang Bixi, Wu Panfeng, Tang Juyu, Fu Jinfei
机构信息
Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
出版信息
Heliyon. 2023 Feb 10;9(2):e13599. doi: 10.1016/j.heliyon.2023.e13599. eCollection 2023 Feb.
Regulation of chromosome condensation 2 (RCC2) is associated with the cell cycle and is a crucial regulator of the chromatin condensation 1 (RCC1) family. The members of this family were normally regulators in the process of DNA replication and nucleocytoplasmic transport. RCC2 overexpression may lead to tumor formation and poor prognosis in some tumors including breast cancer and lung adenocarcinoma. However, the possible role of RCC2 in tumor formation and its prognostic function remains unclear. In this study, expression analysis from databases including The Cancer Genome Atlas (TCGA) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) were combined to perform the first integrative and comprehensive analysis of RCC2 in human pan-cancer. RCC2 was highly expressed in most tumors which may lead to a poor prognosis. RCC2 expression was associated with immune/stromal infiltration, immune checkpoints, tumor mutational burden, and microsatellite instability. Thus, RCC2 could be a novel biomarker for prognosis and a promising cancer therapy target.
染色体凝聚调节因子2（RCC2）与细胞周期相关，是染色质凝聚调节因子1（RCC1）家族的关键调节因子。该家族成员通常是DNA复制和核质运输过程中的调节因子。RCC2过表达可能导致包括乳腺癌和肺腺癌在内的某些肿瘤的形成和预后不良。然而，RCC2在肿瘤形成中的可能作用及其预后功能仍不清楚。在本研究中，结合来自包括癌症基因组图谱（TCGA）和临床蛋白质组肿瘤分析联盟（CPTAC）等数据库的表达分析，对RCC2在人类泛癌中进行了首次综合全面分析。RCC2在大多数肿瘤中高表达，这可能导致预后不良。RCC2表达与免疫/基质浸润、免疫检查点、肿瘤突变负荷和微卫星不稳定性相关。因此，RCC2可能是一种新的预后生物标志物和有前景的癌症治疗靶点。
Zotero 插件